{
    "root": "3d02b630-f667-47e6-b2d5-f7317b73df2e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": "Doxorubicin Hydrochloride",
    "value": "20250410",
    "ingredients": [
        {
            "name": "DOXORUBICIN HYDROCHLORIDE",
            "code": "82F2G7BL4E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31522"
        },
        {
            "name": "HYDROGENATED SOYBEAN LECITHIN",
            "code": "H1109Z9J4N",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE",
            "code": "3L6NN8ZZKU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "CHOLESTEROL",
            "code": "97C5T2UQ7J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16113"
        },
        {
            "name": "AMMONIUM SULFATE",
            "code": "SU46BAM238",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_62946"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "doxorubicin hydrochloride anthracycline topoisomerase inhibitor indicated : ovarian cancer : failure platinum-based chemotherapy ( 1.1 ) . aids-related kaposi \u2019 sarcoma : failure prior systemic chemotherapy intolerance therapy ( 1.2 ) . multiple myeloma : combination bortezomib patients previously received bortezomib received least one prior therapy ( 1.3 ) .",
        "doid_entities": [
            {
                "text": "ovarian cancer (DOID:2394)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2394"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "sarcoma (DOID:1115)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1115"
            },
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer doxorubicin hydrochloride liposome injection initial rate 1 mg/min minimize risk infusion . infusion-related occur , increase rate infusion complete 1 hour . administer bolus injection undiluted solution ( 2 ) . ovarian cancer : 50 mg/m 2 intravenously every 4 weeks ( 2.2 ) aids-related kaposi \u2019 sarcoma : 20 mg/m 2 intravenously every 3 weeks ( 2.3 ) multiple myeloma : 30 mg/m 2 intravenously day 4 following bortezomib ( 2.4 )",
        "doid_entities": [
            {
                "text": "ovarian cancer (DOID:2394)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2394"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "sarcoma (DOID:1115)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1115"
            },
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "doxorubicin hydrochloride liposome injection sterile , translucent , red liposomal dispersion 10 ml 25 ml glass , single-dose vials . following individually cartoned vials available : table 14 mg vial fill volume vial size ndc # 20 mg vial 10 ml 10 ml 72603-103-01 50 mg vial 25 ml 30 ml 72603-200-01 refrigerate unopened vials doxorubicin hydrochloride liposome injection 2\u00b0 8\u00b0c ( 36\u00b0 46\u00b0f ) . freeze . discard unused portion . doxorubicin hydrochloride liposome injection cytotoxic . follow applicable special handling disposal procedures1 .",
    "adverseReactions": "doxorubicin hydrochloride liposome injection contraindicated patients history severe hypersensitivity , including anaphylaxis , doxorubicin hydrochloride [ ( 5.2 ) ] .",
    "indications_original": "Doxorubicin hydrochloride is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer: After failure of platinum-based chemotherapy (1.1). AIDS-related Kaposi\u2019s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy (1.2). Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy (1.3).",
    "contraindications_original": "Administer doxorubicin hydrochloride liposome\u00a0injection at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related reactions occur, increase rate of infusion to complete administration over 1 hour. Do not administer as bolus injection or undiluted solution (2). Ovarian cancer: 50 mg/m 2 intravenously every 4 weeks (2.2) AIDS-related Kaposi\u2019s Sarcoma: 20 mg/m 2 intravenously every 3 weeks (2.3) Multiple Myeloma: 30 mg/m 2 intravenously on day 4 following bortezomib (2.4)",
    "warningsAndPrecautions_original": "Doxorubicin hydrochloride liposome injection is a sterile, translucent, red liposomal dispersion in 10 mL or 25 mL glass, single-dose vials.\n                      The following individually cartoned vials are available:\n                  \n                     \n                  \n                  \n                     Table 14 \n                     \n                        \n                           mg in vial\n                           fill volume\n                           vial size\n                           NDC #s\n                        \n                        \n                           20 mg vial\n                           10 mL\n                           10 mL\n                           72603-103-01\n                        \n                        \n                           50 mg vial\n                           25 mL\n                           30 mL\n                           72603-200-01\n                        \n                     \n                  \n                  \n                  Refrigerate unopened vials of doxorubicin hydrochloride liposome injection at 2\u00b0 to 8\u00b0C (36\u00b0 to 46\u00b0F). Do not freeze.\u00a0Discard unused portion. Doxorubicin hydrochloride liposome injection is a cytotoxic drug. Follow applicable special handling and disposal procedures1.",
    "adverseReactions_original": "Doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see Warnings and Precautions (5.2)].",
    "drug": [
        {
            "name": "Doxorubicin Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31522"
        }
    ]
}